Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06939322
Recruiting Not applicable

LOG-I - Impact Study of LOG-AFTER Software on Long-term Monitoring of Former Patients (LOG-I - LOG-Impact Study)

NCT06939322 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Angers
Phase
Not applicable
Started
2025-06-06
Last updated
2025-07-02

Condition(s) studied

Pediatric CancerCancer SurvivorHemato-oncologic Patients

Investigational drug(s) / intervention(s)

Use of the Log-AFTER software

Use of the Log-AFTER software: The LOG-AFTER software is used for long-term follow-up care after cancer to empower patients

Study summary

Childhood cancer survivors represent a high-risk population that requires risk-based follow-up. Follow-up recommendations have been harmonized. Education and information practices regarding follow-up recommendations should be personalized, to ensure understanding by all survivors, including those with neurocognitive disorders. Individualized follow-up is necessary to detect complications that may increase morbidity and decrease quality of life, or even increase the risk of early mortality.

In France, the LOG-AFTER software was developed in 2017 by university hospital of Angers and Epiconcept (approved health data host). The main differences with the European procedure concern radiotherapy information, the link with the General practitioner (GP), and the possible addition of information and/or access to therapeutic education in a video format. Indeed, there is the possibility of creating an GP account allowing to receive notifications concerning the follow-up of his patient to be scheduled, to have access to his file summary and his personalized follow-up plan, various information and blank prescription models. LOG-I is a study of the impact of the LOG-AFTER software for the "patient/GP" couple on adherence to follow-up recommendations. LOG-I is interested in all former patients with at least 3 recommendations in their personalized follow-up plan, taking into account the specific population of patients cured of a brain tumor.

Eligibility

Sex
ALL
Min age
15 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Previously treated for cancer or malignant hematological pathology before the age of 25 * Without residual disease or with a stable disease without treatment for 5 years or more * Owning a computer, smartphone or equivalent I-Pad/tablet with internet access * Having signed the consent (or their parents if the patient is a minor, or a third party if necessary) * Having 3 or more recommended screenings in their survivorship care plan * No access created to LOG-AFTER before the study or having never connected after opening their account if opening an account dating back 24 months or more at the time of inclusion Exclusion Criteria: * Patient who has relapsed or developed a second cancer with a post-treatment delay \< 5 years * Patient not covered by a health insurance * Patient subject to a legal protection measure, patient deprived of liberty by judicial or administrative decision, patient subject to psychiatric care under duress

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University Hospital of Angers Angers Maine Et Loire Recruiting

More University Hospital, Angers trials in France

RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing Recruiting
V/Q Matching Variations With PEEP in ARDS According to Compliance-based Phenotypes (France) Recruiting
Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation. Recruiting
NAC- NAFLD And Cushing Recruiting
Impact of Optimized Recruitment and Follow-up of Patients With Pseudoxanthoma Elasticum (PXE) Recruiting

Other trials for the same condition

Adapted Physical Activity for Children Treated With Cancer and Insulin Sensitivity Recruiting
Virtual Reality for Children in Radiotherapy (REVER) Recruiting
Integrative Molecular Analysis of Individual Radiosensitivity in Pediatric Oncology Recruiting
Hospital Based Registry of Childhood Cancer in Pediatric Oncology Units in French Speaking Africa Recruiting
Analysis of Risk Factors for Hearing Loss in Survivors of Cancer Occurred During Childhood, Adolescence or Young Adulthood Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06939322 on ClinicalTrials.gov ↗ ← All trials in France